Heat Biologics Inc (HTBX) |
|
7.68 -0.23 (-2.91%)
|
03-07 04:44 |
|
Open: |
7.8 |
Pre. Close: |
7.91 |
|
High:
|
7.88 |
Low:
|
6.7299 |
|
Volume:
|
1,567,094 |
Market Cap:
|
175M |
|
|
|
|
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Durham, North Carolina and currently employs 30 full-time employees. The firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. The company is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.889 - 7.939 |
7.939 - 7.974 |
|
Low:
|
6.628 - 6.681 |
6.681 - 6.719 |
|
Close:
|
7.6 - 7.689 |
7.689 - 7.752 |
|
Technical analysis |
as of: 2021-03-05 5:09:07 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 15.20 One year: 19.86 |
| Support: |
Support1: 6.56 Support2: 5.46 |
| Resistance: |
Resistance1: 13.01 Resistance2: 17.00 |
| Pivot: |
8.87 |
| Moving Average: |
MA(5): 8.05 MA(20): 9.22 
MA(100): 7.58 MA(250): 7.60 |
| MACD: |
MACD(12,26): -0.02 Signal(9): 0.25 |
| Stochastic oscillator: |
%K(14,3): 14.26 %D(3): 11.43 |
| RSI: |
RSI(14): 44.79 |
| 52-week: |
High: 30.10 Low: 3.22 Change(%): 27.6 |
| Average Vol(K): |
3-Month: 317008 10-Days: 149254 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.HTBX has closed above bottom band by 22.9%. Bollinger Bands are 62.5% wider than normal. The large width of the bands suggest high volatility as compared to HTBX's normal range. The bands have been in this wide range for 17 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 03 Mar 2021
Should You Buy Heat Biologics Inc (HTBX) Stock Wednesday Morning? - InvestorsObserver
Wed, 03 Mar 2021
Heat Biologics (HTBX) Jumps Sharply On Sudden Stock Upgrade – Own Snap - Own Snap
Fri, 26 Feb 2021
Heat Biologics - Consensus Indicates Potential 245.7% Upside - DirectorsTalk Interviews
Fri, 26 Feb 2021
$590,000.00 in Sales Expected for Heat Biologics, Inc. (NASDAQ:HTBX) This Quarter - MarketBeat
Thu, 18 Feb 2021
Heat Biologics - Consensus Indicates Potential 155.9% Upside - DirectorsTalk Interviews
Tue, 16 Feb 2021
HTBX: HS-110 Phase 2 Interim Data - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
23 |
| Shares Float (M) |
22 |
|
% Held by Insiders
|
3.01 |
|
% Held by Institutions
|
12.27 |
|
Shares Short (K)
|
2,100 |
|
Shares Short P. Month (K)
|
2,180 |
Stock Financials |
|
EPS
|
-1.990 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
5.420 |
|
Profit Margin
|
|
|
Operating Margin
|
-496.59 |
|
Return on Assets (ttm)
|
-17.5 |
|
Return on Equity (ttm)
|
-33.7 |
|
Qtrly Rev. Growth
|
13096.6 |
|
Gross Profit (p.s.)
|
-0.436 |
|
Sales Per Share
|
0.190 |
|
EBITDA (p.s.)
|
-0.932 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-16 |
|
Levered Free Cash Flow (M)
|
-10 |
Stock Valuations |
|
PE Ratio
|
-3.86 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.42 |
|
Price to Sales
|
40.40 |
|
Price to Cash Flow
|
-11.08 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
